A comparison of brain and serum pharmacokinetics of R-fluoxetine and racemic fluoxetine: A 19-F MRS study (Q28249891)

1

0 references

Mark E Schmidt

2

0 references

John Hennen

3

0 references

Rosemond A Villafuerte

4

0 references

Michelle L Butman

5

0 references

Pierre Tran

6

0 references

Lynn T Kerner

7

0 references

Bruce Cohen

What Clinicians Should Know About the QT Interval

8

0 references

language of work or name

English

0 references

publication date

August 2005

0 references

published in

Neuropsychopharmacology

0 references

volume

30

0 references

issue

8

0 references

page(s)

1576-83

0 references

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300749

Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300749

Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300749

Quantitation of dexfenfluramine/d-norfenfluramine concentration in primate brain using 19F NMR spectroscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300749

Measurement of human brain dexfenfluramine concentration by 19F magnetic resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300749

Transverse low-field RF coils in MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300749

Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300749

Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300749

Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300749

Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300749

Routine quantitative analysis of brain and cerebrospinal fluid spaces with MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300749

R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300749

Stereochemistry in Drug Action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300749

Effects of three fluoroquinolones on QT interval in healthy adults after single doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300749

Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300749

Absolute configurations and pharmacological activities of the optical isomers of fluoxetine, a selective serotonin-uptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300749

Treatment approaches to major depressive disorder relapse. Part 1: dose increase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300749

Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300749

Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300749

Antidepressant Drugs in the Elderly — Rôle of the Cytochrome P450 2D6

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300749

Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300749

The effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and risk-benefit profile of fluoxetine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300749

inferred from DOI database lookup

7 January 2021

based on heuristic

Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300749

inferred from DOI database lookup

7 January 2021

based on heuristic

Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300749